KATHMANDU, Oct 3: State Minister for Health and Population, Umesh Shrestha has said that children below the age of 18 will be administered vaccines against COVID-19 right after Dashain.

CHICAGO, Sept 16: New data from Moderna Inc's (MRNA.O) large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday.

TOKYO, Sept 1: Japan's Kanagawa prefecture said it has found another vial of Moderna Inc's (MRNA.O) COVID-19 vaccine suspected of containing a foreign substance and has put the rest of the lot on hold.

TOKYO, August 31: Japan's health minister said on Tuesday it was highly likely that foreign matter found in Moderna Inc (MRNA.O) COVID-19 vaccines in the southern prefecture of Okinawa were caused when needles were stuck into the vials.

August 26: Moderna Inc (MRNA.O) said on Wednesday it has withheld supply of about 1.63 million doses of its COVID-19 vaccine in Japan after a report of contamination of vials with particulate matter, which it suspects involves a production line in Spain.

August 10: The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.

August 5: Moderna Inc (MRNA.O) said on Thursday its COVID-19 shot was about 93% effective through six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial.

USA, May 26: Moderna said Tuesday its COVID-19 vaccine strongly protects kids as young as 12, a step that could put the shot on track to become the second option for that age group in the U.S.

FRANKFURT, Nov 22: Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

MASSACHUSETTS, Nov 17: Moderna Inc’s experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second U.S. drugmaker to report results that far exceed expectations.